Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained an $85 price target.

April 09, 2024 | 10:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Apellis Pharmaceuticals with an $85 price target.
The reiteration of a Buy rating and maintenance of an $85 price target by a reputable analyst like Joseph Stringer could positively influence investor sentiment towards Apellis Pharmaceuticals. This endorsement may lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100